REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > 1,3-diazines (e.g., Pyrimidines, Etc.) 1,3-diazines (e.g., Pyrimidines, Etc.)1,3-diazines (e.g., Pyrimidines, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010534 - Novel compounds The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. ... 01/11/07 - 20070010533 - Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)-(VI) as recited throughout the application. ... 01/11/07 - 20070010532 - 3-pyridylcarboxamide derivatives as pesticidal agents The invention relates to a 3- pyridylcarboxamide derivative of formula (I): wherein the various symbols are as defined in the description, to compositions thereof, to their use for the control of pests, and to processes for their preparation. ... 01/04/07 - 20070004758 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well ... 12/28/06 - 20060293344 - Therapeutic compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents. ... 12/28/06 - 20060293343 - Pyrimidine derivatives The invention provides a compound represented by the following general formula (1), possible stereoisomers thereof or racemates thereof, pharmacologically acceptable salts thereof, hydrates thereof, solvated compounds thereof, or prodrugs thereof, ... 12/28/06 - 20060293342 - Tie-2 modulators and methods of use The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and ... 12/21/06 - 20060287340 - 2-aminoquinoline derivatives [in which R1 and R2 either stand for lower alkyl, lower cycloalkyl, etc., or R1 and R2 together form an aliphatic nitrogen-containing heterocycle with the nitrogen atom to which they bind; R3, R4, R5, R6 and R7 stand for hydrogen, lower alkyl, etc.; R8 stands for lower alkyl, lower alkyloxy, ... 12/14/06 - 20060281765 - Process for producing substituted aniline compound (in the formula, R1, R2, R3, X and Y have the same definitions as given above; and Ac is an acetyl group) and subjecting this compound to reduction and deacetylation, advantageously in industry. ... 12/14/06 - 20060281764 - Aminopyrimidines as kinase modulators where R3, B, Z, Q, p, q and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a ... 12/14/06 - 20060281763 - Carboxamide inhibitors of tgfbeta Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C-4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGFβ activity. ... 12/14/06 - 20060281762 - 1,3-benzoxazolyl derivatives as kinase inhibitors The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases. (I) ... 12/07/06 - 20060276488 - N-heterocyclic inhibitors of tnf-alpha expression Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed. ... 12/07/06 - 20060276487 - New compounds useful for dpp-iv enzyme inhibition The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX). ... 12/07/06 - 20060276486 - Lklf/klf2 gene expression promoter Expression of LKLF/KLF2 gene can be promoted by administering, as an active ingredient, an effective amount of a substance capable of inhibiting the mevalonic acid metabolic pathway. ... 11/30/06 - 20060270688 - Compounds for modulating trpv3 function The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. ... 11/23/06 - 20060264445 - Compounds capable of activating cholinergic receptors Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine. ... 10/26/06 - 20060241125 - Compounds useful in therapy R9 and R10 independently represent H, C1-6alkyl, C1-6alkyloxy, CN, CF3 or halo; may be useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome. ... 10/05/06 - 20060223833 - Thiazolidinones, their production and use as pharmaceutical agents their production and use as inhibitors of polo-like kinases (Plk) for treating various diseases. ... 09/28/06 - 20060217399 - Phenyl quinolines and their use as estrogenic agents R1, R2, R3, R4, R5, and R6 are as defined in the specification, or a N-oxide thereof or a pharmaceutically acceptable salt thereof or a prodrug thereof. ... 09/28/06 - 20060217398 - Substituted pyrimidine derivatives a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the ... 09/14/06 - 20060205740 - Chemical compounds The present invention discloses pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such pyrimidine derivatives are useful in the treatment of diseases associated with inappropriate ErbB family kinase. ... 08/17/06 - 20060183754 - Amide bridged piphenyl or biazaphenyl derivatives and R1 to R13, X1, X2, m and n are defined in the description, and all pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which ... 08/17/06 - 20060183753 - Use of substituted 2,5-diamidoindoles for the treatment of urological diseases The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.RCK 41-Foreign Countries ... 08/10/06 - 20060178375 - Heteroaryloxy nitrogenous saturated heterocyclic derivative Compound of the formula: (I) [wherein each of X1, X2, and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse ... 08/03/06 - 20060173024 - Compositions and methods for treating heart failure Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. ... 08/03/06 - 20060173023 - 2-(bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... 08/03/06 - 20060173022 - Heterocyclic amides, method for the production thereof, substances containing said heterocyclic amides, and use thereof as pesticides wherein: A is CH or N; Y is O or S; n is 0 or 1; R1 is (C1-C4)-haloalkyl; R2 and R3 are identical or different and are hydrogen, (C1-C4)-alkyl, (C1-C4)-haloalkyl or halogen; R4 is hydrogen, (C1-C10)-alkyl, (C3-C10)-cycloalkyl, (C3-C10)-alkenyl or (C3-C10)-alkynyl, where in the alkyl, cycloalkyl, alkenyl or alkynyl groups ... 07/27/06 - 20060167016 - 2,5-disubstituted pyrimidine derivatives The present invention relates to novel 2,5-disubstituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases. ... 06/08/06 - 20060122197 - Amido compounds and their use as pharmaceuticals The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or ... 06/08/06 - 20060122196 - Gyrase inhibitors and uses thereof The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. ... 06/01/06 - 20060116386 - Oxazolidinones as antibacterial agents A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: Wherein C is selected from (D) and (E), R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected from for example H, F, CF3, ... 05/25/06 - 20060111371 - Protein tyrosine kinase inhibitors wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group ... 05/18/06 - 20060106032 - Synthesis of n2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents Novel compounds of 2-(substituted arylmethyl)-3-(substituted phenyl)-2H-indazoles and 1-(substituted arylmethyl)-3-(substituted phenyl)-1H-indazoles are synthesized, and useful as anti-angiogenic agents. ... 05/11/06 - 20060100219 - Novel bradykinin-b1 antagonists, process for their preparation and their use as medicaments in which A, Ar, G, Q, R1 and R4 are as defined in claim 1, their enantiomers, their diastereomers, their mixtures and their salts, in particular their physiologically acceptable salts with organic or inorganic acids or bases having useful properties, their preparation, medicaments comprising the pharmacologically effective compounds, their preparation ... 05/11/06 - 20060100218 - Pde4b inhibitors Compounds are described that are active on PDE4. Also described are crystal structures of PDE4B determined using X-ray crystallography, the use of PDE4B crystals and strucural information for identifying molecular scaffolds, for developing ligands that bind to and modulate PDE4B, and for identifying improved ligands based on known ligands. ... 05/11/06 - 20060100217 - Preparation of 4-haloalkylnicotinamides Z is the same or different and is O, S or NR1, to a ring-closing reaction and simultaneous hydrolysis in the presence of a strong acid. The compounds of the formula (I) are useful as intermediates for preparing pesticides. ... 05/04/06 - 20060094732 - Arylvinylazacycloalkane compounds and methods of preparation and use thereof Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the ... 05/04/06 - 20060094731 - New medicament The present invention relates to the use of a compound of formula (1) wherein R1 is pyridyl or thiazolyl, any of which may optionally be substituted with C1-8alkyl or C2-8alkenyl: and a) R2 is methoxy and n is zero or one; or b) R2 is chlorine and n is zero ... 05/04/06 - 20060094730 - Water-soluble thalidomine derivatives Thalidomide derivative (I) and their bases or salts are new: where R represents CHR1NR2R3, CHR1NR4C(O)CHR5NR2R3, W or CHR5NR4C(O)W, where R1, R4 and R5 represent independently each other H, C1-4 alkyl, R2 is a C1-4 alkyl, R3 is a C1-4 alkyl, or R2 and R3 together represents 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, ... 04/27/06 - 20060089371 - Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist in which the groups Q1-Q4, Ar, and R1-R7 are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment ... 04/13/06 - 20060079535 - 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel Compositions of matter comprising 5-phenoxyalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or animal subjects, including autoimmune diseases. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds ... 04/06/06 - 20060074092 - Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases or a pharmaceutically acceptable salt or ester thereof (I), wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g., various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors. ... 03/30/06 - 20060069105 - Protein tyrosine kinase inhibitors wherein R1 and R2 are independently selected from the group consisting of: ... 03/23/06 - 20060063783 - Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors A compound of formula (1): wherein B is optionally substituted C2-4alkenyl or C2-4alkynyl; useful in the inhibition of one or more metalloproteinases and in particular TACE. ... 03/16/06 - 20060058319 - Pyrazolopyridines, process for their preparation and use as therapeutic compounds wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents. ... 03/16/06 - 20060058318 - Prodrugs of an erk protein kinase inhibitor The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. ... 03/16/06 - 20060058317 - Oxazolidinone derivatives as antibacterial A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I), wherein C is selected from D and E, formula (D), formula (E), R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected ... 03/16/06 - 20060058316 - 4-oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition. ... 03/09/06 - 20060052399 - Oxazolidinone derivatives as antibacterial agents A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydsolysable ester thereof: formula (I) wherein C is selected from D and E, formula (D), formula (E) R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected ... 03/09/06 - 20060052398 - Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same in which R1, R2, R3, R4 and G have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them. ... 03/09/06 - 20060052397 - Carbamate-substituted pyrazolopyridines The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction. ... 02/23/06 - 20060040956 - Substituted alkylamine derivatives and methods of use Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject ... 02/23/06 - 20060040955 - 4-pyrimidineamine compounds and their uses as anti-proliferative agents The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers. ... 02/09/06 - 20060030570 - Method for treating cryptorchidism The present invention relates to a method and pharmaceutical composition for the treatment of male individuals suffering from cryptorchidism comprising administering to said individuals an effective amount of an aromatase inhibitor, preferably finrozole. ... 02/02/06 - 20060025425 - Benzimidazole and pyridylimidazole derivatives This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization ... 02/02/06 - 20060025424 - Gyrase inhibitors and uses thereof The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. ... 01/26/06 - 20060019967 - Sars cov main protease inhibitors wherein A1, A2, and L are defined herein, and use of the compound in treating coronavirus infection, hepatitis C virus infection, hemophilia, vascular restenosis, or hypertension. ... 01/19/06 - 20060014761 - Compounds, compositions and methods Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. ... 01/19/06 - 20060014760 - Compounds and methods of use to treat infectious diseases The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds ... 01/19/06 - 20060014759 - Methods for the use of inhibitors of cytosolic phospholipase a2 and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, ... 12/29/05 - 20050288308 - 11b-hsd1 inhibitors for the treatment of diabetes as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions. ... 12/29/05 - 20050288307 - Anti-viral compounds The present invention relates to the use of 2-substituted 4-heteroaryl-pyrimidines and related compounds in the treatment of viral disorders. ... 12/29/05 - 20050288306 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well ... 12/29/05 - 20050288305 - N-biarylmethyl aminocycloalkanecarboxamide derivatives N-Biarylmethylainocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... 12/22/05 - 20050282825 - Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient. ... 12/22/05 - 20050282824 - Substituted pyrimidines as inhibitors of bacterial type iii protein secretion systems In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial ... 12/22/05 - 20050282823 - Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as ... 12/15/05 - 20050277654 - 4,5-disubstituted-2-aryl pyrimidines wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to ... // - 4,5-disubstituted-2-arylpyrimidines of Formula I and Formula II are provided: - ... 12/15/05 - 20050277653 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well ... 12/15/05 - 20050277652 - Novel pyridine derivative and pyrimidine derivative [R1 represents C1-6 alkyl or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents C1-6 alkyl or the like; V1 represents oxygen or ... 12/08/05 - 20050272747 - Preparation of triazoles by organometallic addition to ketones and intermediates therefor wherein R1 and “Het” are as previously defined for a compound of the formula (I) and X is chloro, bromo or iodo, in the presence of zinc, iodine and/or a Lewis acid and an aprotic organic solvent: said process being optionally followed by conversion of the compound of the formula ... 11/24/05 - 20050261313 - Substituted alkylamine derivatives and methods of use Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention ... 11/17/05 - 20050256137 - Pyridone compounds as inhibitors of bacterial type iii protien secreation systems In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial ... 11/17/05 - 20050256136 - Gyrase inhibitors and uses thereof The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with ... 11/10/05 - 20050250792 - Substituted piperidine compounds useful as modulators of chemokine receptor activity wherein R1, R2, R3, R6, Z, Q, m, n, X1, X2, X3, X4 and T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions. ... 11/03/05 - 20050245543 - Histamine-3 receptor antagonists as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound ... 10/20/05 - 20050234074 - Dibenzo chromene derivatives and their use as erbeta selective ligands where R1 R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification. ... 10/20/05 - 20050234073 - Methods of inhibiting inflammation The invention provides a method of inhibiting inflammation in a mammal, by administering to the mammal composition containing a compound which inhibits the expression or activity of a microsomal triglyceride transfer protein. ... 10/06/05 - 20050222170 - Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators The invention relates to novel chemical compounds of formula (I), which stimulate soluble guanylate cyclase, to the production and use thereof as medicament, particularly in the treatment of cardiovascular diseases and/or sexual dysfunction (I), wherein R1″ represents chlorine, cyano, trifluoromethyl or methoxy and R2 represents hydrogen or fluorine or R1 ... 09/29/05 - 20050215568 - Substituted oxetanes, method of making, and method of use thereof Oxetane-containing nucleosides, particularly non-reducing psiconucleoside oxetanes are described herein. Therapeutic application of these oxetane compounds toward the treatment of nucleoside analog related disorders such as disorders involving cellular proliferation and infection are also described. ... 09/01/05 - 20050192295 - Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents. ... 09/01/05 - 20050192294 - Heteroarylaminopyrazole derivatives useful for the treatment of diabetes The present invention relates to heteroarylaminopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders. ... 09/01/05 - 20050192293 - Amide compounds as ion channel ligands and uses thereof The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. ... 09/01/05 - 20050192292 - Pyrrolidone carboxamides Pyrrolidone carboxamides of formula (I) where R2=a group of formula (a) or (b), R5=phenyl, heteroalkyl, aryloxy, alkoxy, alkanoyl or —NR6R7 and R1, X, R3, R4, R6 and R7 have the meanings given in the description and the claims, pharmaceutically applicable acid addition salts with basic compounds of formula (I), pharmaceutically ... 08/18/05 - 20050182074 - Combination of voriconazole and an antifungal cyp2c19 inhibitor The invention provides a therapeutic combination comprising voriconazole and an antifungal CYP2C19 inhibitor in specific quantities and weight ratios. Pharmaceutical compositions, unit dosage forms and kits comprising voriconazole and an antifungal CYP2C19 inhibitor, and their use in the treatment of fungal infections, are also provided. ... 08/18/05 - 20050182073 - 5-phenylpyrimidines The present invention relates to novel 5-phenylpyrimidines, to a plurality of processes for their preparation, and to their use for controlling unwanted microorganisms. The invention further relates to novel intermediates and to processes for their preparation. ... 08/18/05 - 20050182072 - Substituted heterocyclic compounds and methods of use The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. ... 08/11/05 - 20050176734 - Method for producing 4-haloalkyl nicotinic acid amides where R1 is as defined above, R2 is the same or different and is (C1-C6)-alkyl and Z is the same or different and is O, S or NR1, to a ring-closing reaction and simultaneous hydrolysis in the presence of a strong acid. ... 08/04/05 - 20050171121 - Germicidal compositions containing phenylmalonaldehyde-type compounds, or mixtures of phenylmalonaldehyde-type compounds and phthalaldehydes, and methods of using such compositions for disinfection or sterilization wherein Ar is an aryl group that is selected from the group consisting of phenyl, 4-pyrimidinyl, and 2-(2-nitro-3-formyl-phenyl). In a further aspect, the composition may also include a germicidal efficacy enhancer such as isophthalaldehyde or a combination of isophthalaldehyde and terephthalaldehyde. ... 07/28/05 - 20050165028 - Vanilloid receptor ligands and their use in treatments N-Bicyclic amides and derivatives thereof and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin ... 07/28/05 - 20050165027 - Derivatives of [6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease. ... 07/14/05 - 20050153987 - Compounds The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy. ... 07/14/05 - 20050153986 - Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the ... 07/07/05 - 20050148601 - Neurokinin-3 receptor modulators: diaryl imidazole derivatives wherein the variables are as defined herein. Also provided are pharmaceutical compositions comprising such compounds, and methods for treating patients suffering from a disorder responsive to neurokinin-3 receptor modulation. NK-3 receptor modulators provided herein are also useful as probes for the localization of NK-3 receptors. ... 07/07/05 - 20050148600 - Methods for the treatment of obesity Methods are provided for treating or preventing obesity by inhibiting the activity of lysophosphatidic acyltransferase β (LPAAT-β). ... 06/23/05 - 20050137212 - Hppars activators Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta (“hPPARs”) comprising ... 06/16/05 - 20050130991 - Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof in which n is an integer ranging from 2 to 12; R1 is a linear or branched, saturated or unsaturated alkyl radical, optionally substituted with a group —OR′, —NR′R″ or —COOR′, R1 having from 1 to 20 carbon atoms, or is NR′R″; R2 is hydrogen, —NR3R4, —OR3, or —SR3, wherein ... 06/09/05 - 20050124634 - 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease The present invention provides certain substituted 1,4-dihydropyridine compounds, including pure enantiomeric forms and pharmaceutical formulations thereof. These compounds provide for elevation of α-MyHC protein levels and α-MyHC mRNA levels, and most frequently these same compounds provide simultaneous lowering of β-MyHC protein levels and β-MyHC mRNA levels. Thus, these compounds may ... 06/09/05 - 20050124633 - 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease The present invention provides certain substituted 1,4-dihydropyridine compounds, including pure enantiomeric forms and pharmaceutical formulations thereof. These compounds provide for elevation of α-MyHC protein levels and α-MyHC mRNA levels, and most frequently these same compounds provide simultaneous lowering of β-MyHC protein levels and β-MyHC mRNA levels. Thus, these compounds may ... 06/02/05 - 20050119278 - Anti-angiogenesis methods in which n is 0, 1, 2, or 3; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, or R1 ... 06/02/05 - 20050119277 - Benzazole derivatives for the treatment of scleroderma The present invention is related to the use of benzazole derivatives of formula (I) for the treatment and/or prevention of scleroderma and its therapeutic implications selected in the group consisting of systemic sclerosis, scleroderma-like disoders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloid and other scarring/wound healing abnormalities, ... ### FreshPatents.com Support |